Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Docetaxel

HY-B0011

Docetaxel

Docetaxel Chemical Structure

Docetaxel(Taxotere), an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $66 In-stock
100 mg $60 In-stock
200 mg $85 In-stock
500 mg Get quote
1 g Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €65 In-stock
100 mg €59 In-stock
200 mg €83 In-stock
500 mg Get quote
1 g Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Docetaxel
Cat. No.: HY-B0011

Docetaxel Data Sheet

  • View current batch:

    Purity: 98.57%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of Docetaxel

Docetaxel(Taxotere), an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules.
IC50 Value:
Target: Microtubule/Tubulin
in vitro: IC50 concentrations (reducing survival by 50%) ranged from 0.13-3.3 ng/ml, with three neuroblastoma lines proving most sensitive and three breast and two colon carcinoma lines showing least sensitivity [1]. Docetaxel was shown to promote the assembly of microtubule protein without GTP in vitro, but no inhibitory effect on DNA, RNA and protein synthesis [2]. Gene expression changes induced by paclitaxel treatment were mainly enriched in actin cytoskeleton (ACTC1, MYL2 and MYH2), tyrosine-protein kinases (ERRB4, KIT and TIE1) and focal adhesion pathway (MYL2, IGF1 and FLT1), while the expression alterations responding to docetaxel were highly co-related to cell surface receptor linked signal transduction (SHH, DRD5 and ADM2), cytokine-cytokine receptor interaction (IL1A and IL6) and cell cycleregulation (CCNB1, CCNE2 and PCNA) [4].
in vivo:  The patients, between 15 and 80 years old with performance status (PS) of 0-2, received at least two cycles of docetaxel 60 mg m-2 intravenously at 3-4 week intervals [3]. Intestinal damage after repeated dosing of docetaxel (20 mg/kg) for 3 weeks was more severe at 14HALO than at 2HALO (hours after light on). The intestinal protein expressions of Wee1, phosphorylated CDK1, and cleaved Caspase-3 were higher in the 14HALO group than in the 2HALO group, while that of survivin was lower in the 14HALO group [5].
Toxicity: Twenty-five patients were enrolled. Overall, 13/25 (52 %, 95 % CI 34-70) completed 4 cycles, and 19/25 (76 %, 95 % CI 60-87) completed ≥3 cycles. Twenty of 25 patients (80 %) experienced a Grade 3 or 4 adverse event [6].

Chemical Information

M.Wt 807.88 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₄₃H₅₃NO₁₄
CAS No 114977-28-5
Solvent & Solubility

DMSO: ≥ 35 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.2378 mL 6.1890 mL 12.3781 mL
5 mM 0.2476 mL 1.2378 mL 2.4756 mL
10 mM 0.1238 mL 0.6189 mL 1.2378 mL

Clinical Information of Docetaxel

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Docetaxel Sanofi Hormone refractory prostate cancer 31-JAN-06 Phase 4 15-JUN-10
Hoffmann-La Roche Inc Breast tumor 31-AUG-05 31-JUL-09 Phase 4 16-AUG-11
Spanish Breast Cancer Research Group Metastatic breast cancer 31-OCT-02 01-DEC-06 Phase 4 25-OCT-13
Simcere Pharmaceutical Group Non-small-cell lung cancer 31-OCT-08 31-OCT-10 Phase 4 23-OCT-13
Hoffmann-La Roche AG Breast tumor 12-JUL-04 Phase 4 13-SEP-13

References on Docetaxel

Other Forms

Inhibitor Kit

Related Microtubule/Tubulin Products

  • 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • 10-Oxo Docetaxel

    10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

  • 2-Methoxyestradiol

    2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.

  • 4'-Demethylepipodophyllotoxin

    4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.

  • 7-Epi-10-oxo-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

  • 7-Epi-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

  • 7-xylosyltaxol

    7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.

  • ABT-751

    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.

  • Auristatin E

    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

  • Auristatin F

    Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.

MORE